Dumusc Alexandre, Ribi Camillo
Service de rhumatologie, Département de l'appareil locomoteur, CHUV, 1011 Lausanne.
Service d'immunologie et allergie, Département de médecine, CHUV, 1011 Lausanne.
Rev Med Suisse. 2021 Mar 10;17(729):477-480.
Sjögren's syndrome (SS) is an auto-immune condition involving salivary and lacrymal glands leading to dry mouth and dry eyes symptoms. Some patients also present with systemic manifestations. Diagnosis of SS is made after clinical, serological, and histological assessment according to the American College of Rheumatology and European League Against Rheumatism (EULAR) classification criteria. Recent clinical trials showed a significant decrease of systemic activity of SS in patients treated with iscalimab (anti-CD40) and ianalumab (anti-BAFF-R). These results need to be confirmed in larger studies. However, two phase 3 randomized trials did not show efficacy treating SS with abatacept. We also describe in this article the first EULAR recommendations on SS management.
干燥综合征（SS）是一种自身免疫性疾病，累及唾液腺和泪腺，导致口干和眼干症状。一些患者还会出现全身表现。根据美国风湿病学会和欧洲抗风湿病联盟（EULAR）的分类标准，在进行临床、血清学和组织学评估后做出SS的诊断。最近的临床试验表明，接受伊斯卡利单抗（抗CD40）和伊纳鲁单抗（抗BAFF-R）治疗的患者中，SS的全身活动度显著降低。这些结果需要在更大规模的研究中得到证实。然而，两项3期随机试验未显示阿巴西普治疗SS有效。我们还在本文中描述了EULAR关于SS管理的首份建议。
